Novo Nordisk's share price dropped 19% amidst growing competition from Eli Lilly in the diabetes and weight-loss drug market.

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
Tagged , , , , , , , , , ,